GrantPingOpportunity
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
- Agency
- National Institutes of Health
- Number
- PAR-25-226
- Opens
- Nov 22, 2024
- Closes
- Nov 19, 2026
- Status
- posted
- Source
- View the official announcement →
GrantPing organises and filters this listing. The official announcement is the authoritative record — check it for eligibility and full requirements.
Get these before the deadline
GrantPing emails you only the opportunities that match your keywords, soonest close date first. Free weekly digest, no account needed.
Get alertsMore from National Institutes of Health
- NIH Director's Early Independence Award (DP5 Clinical Trial Optional) closes 2026-09-10
- NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical… closes 2026-09-18
- NCI Community Oncology Research Program (NCORP) Academic Community Sites (UG1… closes 2026-09-18
- NCI Community Oncology Research Program (NCORP) Community Sites (UG1 Clinical… closes 2026-09-18
- Atopic Dermatitis Research Network (ADRN) (U19 Clinical Trial Optional) closes 2026-09-24
- National Institute of General Medical Sciences Predoctoral Basic Biomedical… closes 2026-09-25